| Reporting Organization: | International AIDS Society |
|---|---|
| Total Budget ($CAD): | $ 340,000 |
| Timeframe: | March 30, 2015 - December 31, 2015 |
| Status: | Completion |
| Contact Information: | Unspecified |
| Sub-Saharan Africa - $ 299,676.00 (88.14%) | |
|
|
|
| North Africa - $ 40,324.00 (11.86%) | |
|
|
|
| Health Promotion & Education (50 %) | |
|
|
|
| Sexual Health & Rights (50 %) | |
|
|
|
This project supported the 2015 International AIDS Society (IAS) Conference. This conference brings together over 5,000 delegates from across the world for scientific and policy discussion as well as debate, and analysis. In 1996, at the first International AIDS Conference, held in Vancouver, the results of the first trials of HIV triple therapy were discussed, and the beginning of the effective treatment era began. Since that time, new therapies have transformed the lives of millions of people living with HIV worldwide and significant advances have been made in HIV prevention. With GAC’s support, the eighth IAS Conference on HIV Pathogenesis, Treatment, and Prevention was held in Vancouver, from July 19-22, 2015. The two main activities that this project supported are international scholarships for participants from low and middle income countries to attend the conference and program delivery for plenary, symposia and high level sessions.
| Gender and age: | Unspecified |
|---|---|
| Total Direct Population: | Unspecified |
Unspecified
Return to topThe expected outcomes of this project include: (1) improved understanding of barriers to scaling up HIV treatment; 2) improved understanding of the increasing challenges of tuberculosis, viral hepatitis and chronic co-morbidities; and (3) improved support for treatment as prevention.
Results achieved as of December 2015 include: (1) improved understanding of the continued success of treatment scale-up for the prevention of mother to child transmission of HIV through oral presentations that highlighted innovations in implementation science; (2) improved understanding of HIV and hepatitis through sessions that highlighted significant advances and challenges in addressing HIV and hepatitis co-infection; and (3) improved awareness of the effectiveness of HIV treatment through the dissemination of compelling evidence of initiating antiretroviral therapy as early as possible.
